Clinical trialPhase 1Completed
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®23104 in Subjects With Selected Advanced Solid Tumors
- Outcome
- Finished, no results posted
- Phase
- Phase 1
- Status
- Completed
- Study type
- Interventional
- Start
- 1 May 2019
- Ended
- 15 February 2024
- Enrollment
- 198 participants
- Sites
- 18
- Primary outcomes
- Treatment-related adverse events as assessed by CTCAE v4.03
- Sponsor type
- Industry
- Results posted
- No
- Last update
- 5 July 2024
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb23104 monotherapy and combination therapy with ipilimumab in subjects with selected advanced solid tumors.